Epic Sciences Appoints Katherine Atkinson as Chief Commercial Officer
Epic Sciences (Epic), the maker of the world’s first predictive test of drug response in prostate cancer, announced the expansion of its leadership team with the appointment of Katherine Atkinson as chief commercial officer. In this new role, Atkinson will be responsible for the development of Epic’s global commercial strategy by identifying new strategic business opportunities and deepening its existing strategic partnerships.
“As we rapidly transform from a technology platform to a product company and begin to expand into additional markets, Epic will need to have the right commercial leadership in place to guide the next phase of growth. Katherine’s many years of experience in the strategic development of channel partnerships and sales teams make her an ideal fit for this role,” said Murali Prahalad, Ph.D., president and CEO of Epic Sciences.
Atkinson joins Epic Sciences with two decades of life science and healthcare experience. Atkinson was most recently the vice president of business development at Edico Genome, where she established a global channel network and managed strategic partnerships. Prior to Edico Genome, she worked for Illumina. During her tenure at Illumina, she oversaw numerous teams, including molecular biology/PCR sales, Inside Sales, Latin America, and most recently Global Channel Partners, where she developed a high performing Channel Partner program from the ground up, encompassing more than 70 partners covering 130 countries worldwide. Atkinson has also held positions at Fisher Scientific, Thermo Fisher, and Beckman Coulter.
“Epic Sciences has quickly made a name for itself as a leader in personalized medicine by providing predictive tests to support physicians as they manage their patients’ cancer care,” said Katherine. “I’m thrilled to be joining the team who have been working to provide greater certainty around the pivotal clinical decision points in treating cancer to improve patient outcomes."
About Epic Sciences
Epic Sciences, Inc. is developing novel diagnostics to personalize and advance the treatment and management of cancer. Epic Sciences' mission is to enable the rapid and non-invasive detection of genetic and molecular changes in cancer throughout a patient's journey. The company was founded on a powerful platform to identify and characterize rare cells, including circulating tumor cells (CTCs). Epic Sciences' no cell left behind® technology helps match patients to targeted therapies and monitor for drug resistance, so that the best treatment path can be chosen at every clinical decision point. Today, we partner with leading pharmaceutical companies and major cancer centers around the world. Epic Sciences' goal is to commercialize our technology to increase the success rate of cancer drugs in clinical trials and improve patient outcomes by providing physicians real-time information to guide treatment choices. Epic Sciences is headquartered in San Diego.
Media Contact: Jessica Yingling, Ph.D., Little Dog Communications Inc., email@example.com, +1.858.344.8091